Показати скорочений опис матеріалу

CLINICAL ECONOMIC ANALYSIS OF THE FINANCIAL COSTS FOR THE PHARMACOTHERAPY OF ACUTE TONSILLITIS IN THE CONDITIONS OF THE HOSPITAL

КЛІНІКО-ЕКОНОМІЧНИЙ АНАЛІЗ ВИТРАТ НА ФАРМАКОТЕРАПІЮ ГОСТРОГО ТОНЗИЛІТУ В УМОВАХ СТАЦІОНАРУ

dc.creatorMasheiko, A. M.
dc.creatorMakarenko, O. V.
dc.creatorMavrutenkov, V. V.
dc.date2017-02-06
dc.date.accessioned2020-02-26T12:41:44Z
dc.date.available2020-02-26T12:41:44Z
dc.identifierhttps://ojs.tdmu.edu.ua/index.php/pharm-chas/article/view/7121
dc.identifier10.11603/2312-0967.2016.4.7121
dc.identifier.urihttps://repository.tdmu.edu.ua/handle/123456789/15021
dc.descriptionIntroductionAcute tonsillitis (J03 for ICD-10) is one of the most common respiratory diseases in children [1]. According to the medical protocol approved by the Ministry of Health ofUkraine, patients with catarrhal form of acute tonsillitis are provided ambulatory care, but patients with follicular and lacunar tonsillitis forms are treated in a hospital [2].In the latest data of the State Committee of Statistics, 41.1% of the funds in the structure of health care costs are citizens’ private funds [3]. These funds covered 99.6% of the costs for the purchase of pharmaceutical products for outpatient treatment, and 86.7% costs for treatment in a hospital [4]. In addition, it should take note of the low purchasing power of patients, as 36.1% of them are unable to buy the medicines prescribed by a doctor [5].In view, the high rates of morbidity, constantly growing treatment costs and low purchasing power of patients, the purpose of our research was to investigate the expediency of the financial expenses for pharmacotherapy of acute tonsillitis based on the results of retrospective clinical and economic analysis of hospital medical history forms.Materials and methodsThe material of our study were doctors’ prescription sheets (form №003-4/o) of 290 patients with acute tonsillitis aged 2–18 years who were hospitalized in healthcare institutions of Dnipropetrovsk region for the period 2013–2015. Overall, we analyzed 1709 medications. Propriety of medical prescriptions was determined by comparing them to the current Ukrainian medical protocol of care for patients with acute tonsillitis [2] and the Ukraine State Drug Formulary [6]. The expediency of the financial costs for pharmacotherapy of acute tonsillitis was assessed by method the integrated frequency/VEN/ABC analysis [7].Results and discussionThe criterions for classifying medicines to category «V» (vital) were their presence in the medical protocol of care for patients with acute tonsillitis [2] and the the Ukraine State Drug Formulary [6]. The category of «N» (non-essential) included medicines that have been absent at any of the above regulatory documents.Results of the integrated frequency/VEN/ABC-analysis showed that the most costly group A included 15.04% (257 of 1709) medicines category V and 11.29% (193 of 1709) medicines category N. It was found that the basic financial funds had been used for ceftriaxone (J01DD04), local antiseptics (R02AA20) and cefuroxime (J01DC02), among which the most costly ceftriaxone had been prescribed for the largest number of patients. Despite the fact that ceftriaxone is recommended by national standard treatment of acute tonsillitis [2], but it is not the drug of choice for the treatment of this nosology. Ceftriaxone is rational to replace by penicillin or cephalosporin first generation, which have the same clinical efficacy against Streptococcus pyogenes and less cost [11].The frequency of non-essential medicine prescriptions were dominated by the vital medicines. However, the financial costs for vital medicines were slightly greater than for the non-essential medicines, which amounted to 55.66% and 44.34% respectively. Excessive costs for the third-generation cephalosporin pharmacotherapy of acute tonsillitis can be explained by the doctors' intention to protect their patients from clinical failures associated with the penicillin destruction by β-lactamases of tonsils co-pathogenic microorganisms [12].ConclusionsBasic funds were not spent for essential medicines for the treatment of acute tonsillitis. The most often prescribed costly medicine may have been replaced by cheaper ones with similar clinical efficacy.Economically more rational begin pharmacotherapy of acute tonsillitis with penicillins. Сephalosporins second- or third generation and inhibitor-protected penicillins, as antibiotics for second-line therapy, should be prescribed only in cases of recurrent tonsillitis [5].Local antiseptics, probiotics, corticosteroids and dietary supplements had been widely used by doctors. Removal these pharmaceutical products from doctors’ prescription sheets would reduce the financial expenses for pharmacotherapy of acute tonsillitis without affecting its quality.en-US
dc.descriptionУ статті наведено результати інтегрованого частотного^ЕМАВС-аналізу доцільності фінансових витрат на проведення фармакотерапії гострого тонзиліту. Встановлено суттєву перевагу частоти лікарських призначень другорядних засобів (^ над життєво важливими (V) у кількісному вираженні та незначну перевагу життєво важливих засобів над другорядними у вартісному вираженні. З отриманих результатів можна зробити висновок, що основні фінансові кошти не витрачались на необхідні та важливі лікарські засоби для лікування гострого тонзиліту.uk-UA
dc.formatapplication/pdf
dc.languageukr
dc.publisherТернопільський державний медичний університет імені І. Я. Горбачевського МОЗ Україниuk-UA
dc.relationhttps://ojs.tdmu.edu.ua/index.php/pharm-chas/article/view/7121/6572
dc.rightsАвторське право (c) 2017 Фармацевтичний часописuk-UA
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0uk-UA
dc.sourcePharmaceutical Review; No. 4 (2016); 48-53en-US
dc.sourceФармацевтичний часопис; № 4 (2016); 48-53uk-UA
dc.source2414-9926
dc.source2312-0967
dc.source10.11603/2312-0967.2016.4
dc.subjectacute tonsillopharyngitisen-US
dc.subjectfrequency analysisen-US
dc.subjectABC-analysisen-US
dc.subjectVEN-analysisen-US
dc.subjecthospital-based treatment.en-US
dc.subjectгострий тонзилітuk-UA
dc.subjectчастотний аналізuk-UA
dc.subjectАВС-аналізuk-UA
dc.subjectVEN-аналізuk-UA
dc.subjectлікування в умовах стаціонару.uk-UA
dc.titleCLINICAL ECONOMIC ANALYSIS OF THE FINANCIAL COSTS FOR THE PHARMACOTHERAPY OF ACUTE TONSILLITIS IN THE CONDITIONS OF THE HOSPITALen-US
dc.titleКЛІНІКО-ЕКОНОМІЧНИЙ АНАЛІЗ ВИТРАТ НА ФАРМАКОТЕРАПІЮ ГОСТРОГО ТОНЗИЛІТУ В УМОВАХ СТАЦІОНАРУuk-UA
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Долучені файли

ФайлРозмірФорматПереглянути

Даний матеріал не має долучених файлів.

Даний матеріал зустрічається у наступних фондах

Показати скорочений опис матеріалу